|
|
 | |||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
Background In patients with cirrhosis, pharmacologic or endoscopic treatment may control variceal bleeding. However, the effects of early administration of a somatostatin analogue followed by endoscopic treatment are unknown.
Methods We studied the effects of treatment with vapreotide, a somatostatin analogue, begun before endoscopic treatment in 227 patients with cirrhosis who were hospitalized for acute upper gastrointestinal bleeding. The patients were randomly assigned to receive vapreotide (a 50-µg intravenous bolus followed by an infusion at a rate of 50 µg per hour for five days) or placebo within a mean (±SD) of 2.3±1.5 hours after admission. The patients received endoscopic treatment a mean of 2.6±3.3 hours after the infusion was begun. After the exclusion of 31 patients whose bleeding was not caused by portal hypertension, there were 98 patients in each group.
Results At the time of endoscopy, active bleeding was evident in 28 of 91 patients in the vapreotide group (31 percent), as compared with 43 of 93 patients in the placebo group (46 percent, P=0.03); in 12 patients endoscopy was either impossible or showed portal hypertensive gastropathy. During the five-day infusion, the primary objective — survival and control of bleeding — was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P=0.02). The patients in the vapreotide group received significantly fewer blood transfusions (2.0±2.2 vs. 2.8±2.8 units, P=0.04). Overall mortality rates at 42 days were not significantly different in the two groups.
Conclusions In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. However, the use of combination therapy does not affect mortality rates at 42 days.
Source Information
From the Services d'Hépato-Gastroentérologie, Centres Hospitaliers of Angers (P.C.), Nantes (C.M.), Paris (La Pitié–Salpêtrière) (B.B.), La Réunion (P.-P.G.), Poitiers (C.S.), Lille (N.S.-T.), Nancy (J.-P.B.), Nîmes (D.R.), Marseilles (D.B.-F.), and Dijon (P.H.) — all in France; the Laboratoire d'Hémodynamique Splanchnique, Université d'Angers, France (P.C.); Debiopharm, Lausanne, Switzerland (K.B.); and the Service d'Hépatologie and INSERM Unité 481, Hôpital Beaujon, Clichy, France (D.L.). Other authors were T. Poynard, M.D., Paris; P. Verger, M.D., La Réunion; J.C. Paris, M.D., Lille; F. Durand, M.D., and D.-C. Valla, M.D., Clichy; A. Lemaire, M.D., and M. Rouch, M.D., Aurillac; A. Blanchi, M.D., Le Mans; O. Ink, M.D., Soissons; F. Saliba, M.D., Villejuif; G. Galula, M.D., Paris (St. Antoine); B. Pillegand, M.D., Limoges; T. Davion, M.D., Lens; T. Dao, M.D., Caen; C. Bonny, M.D., Clermont-Ferrand; J.-P. Zarski, M.D., Grenoble; and F. Mion, M.D., Lyons — all in France.
Address reprint requests to Dr. Calès at the Service d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, 49033 Angers CEDEX 01, France, or at paul.cales{at}med.univ-angers.fr.
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
